Hinge Health, Inc. (HNGE)
| Market Cap | 7.14B +54.2% |
| Revenue (ttm) | 720.06M +49.8% |
| Net Income | 107.29M |
| EPS | 1.34 |
| Shares Out | 80.69M |
| PE Ratio | 66.26 |
| Forward PE | 33.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,471,849 |
| Open | 89.35 |
| Previous Close | 88.24 |
| Day's Range | 87.29 - 90.70 |
| 52-Week Range | 30.08 - 93.13 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 106.47 (+20.36%) |
| Earnings Date | Aug 4, 2026 |
About HNGE
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, C... [Read more]
Financial Performance
In 2025, Hinge Health's revenue was $587.86 million, an increase of 50.58% compared to the previous year's $390.40 million. Losses were -$424.09 million, 3453.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for HNGE stock is "Buy." The 12-month stock price target is $106.47, which is an increase of 20.36% from the latest price.
News
Hinge Health price target raised to $112 from $85 at Truist
Truist raised the firm’s price target on Hinge Health (HNGE) to $112 from $85 and keeps a Buy rating on the shares after it’s Q2 results and outlook. The company…
Hinge Health price target raised to $105 from $100 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Hinge Health (HNGE) to $105 from $100 and keeps an Outperform rating on the shares.
Hinge Health price target raised to $110 from $75 at RBC Capital
RBC Capital analyst Rishi Jaluria raised the firm’s price target on Hinge Health (HNGE) to $110 from $75 and keeps an Outperform rating on the shares. Hinge Health delivered another…
Hinge Health price target raised to $96 from $90 at Stifel
Stifel raised the firm’s price target on Hinge Health (HNGE) to $96 from $90 and keeps a Buy rating on the shares.
Hinge Health price target raised to $105 from $100 at Canaccord
Canaccord analyst Richard Close raised the firm’s price target on Hinge Health (HNGE) to $105 from $100 and keeps a Buy rating on the shares. The firm updated its model…
Hinge Health price target raised to $107 from $96 at Citizens
Citizens raised the firm’s price target on Hinge Health (HNGE) to $107 from $96 and keeps an Outperform rating on the shares. Hinge Health reinforced its strong growth story with…
Hinge Health price target raised to $100 from $97 at Barclays
Barclays raised the firm’s price target on Hinge Health (HNGE) to $100 from $97 and keeps an Overweight rating on the shares. The company reported a Q2 beat and upped…
Hinge Health reports Q2 non-GAAP EPS 59c, consensus 62c
Reports revenue $213M, consensus $201.49M. “We delivered another strong quarter ahead of expectations, generating $213 million in revenue with 53% year-over-year growth, while more than tripling free ...
Hinge Health sees Q3 revenue $223M-$225M, consensus $211.5M
The company said, “We expect revenue to be between $223 million and $225 million, reflecting year-over-year growth of 45% at the midpoint. We expect non-GAAP income from operations to be…
Hinge Health sees FY26 revenue $856M-$860M, consensus $822.16M
The company said, “We are raising our revenue guidance to be between $856 million and $860 million, reflecting year-over-year growth of 46% at the midpoint. We are raising our non-GAAP…
Hinge Health board approves $300M increase to share repurchase program
On November 10, 2025, our board of directors approved a share repurchase program with authorization to purchase up to $250 million of our Class A common stock. As of July…
Hinge Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 53% revenue growth, margin expansion, and strong free cash flow, driven by robust enterprise and SMB performance, new product launches in migraine and GI, and the acquisition of Cylinder Health. Guidance for 2026 was raised, with continued focus on multi-product expansion and capital returns.
Hinge Health Earnings release: Q2 2026
Hinge Health released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Hinge Health Slides: Q2 2026
Hinge Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Hinge Health Quarterly report: Q2 2026
Hinge Health has published its Q2 2026 quarterly earnings report on August 4, 2026.
Hinge Health to acquire Cylinder Health for $105M in cash consideration
Hinge Health (HNGE) announced that it has signed a definitive agreement to acquire Cylinder Health, Inc, a leader in virtual-first digestive healthcare, for $105 million in cash consideration. With th...
Hinge Health to acquire Cylinder Health, expanding into gastrointestinal care
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced that it has signed a definitive agreement to acquire Cylinder Health, Inc, a leader in virtual-first digestive healthcar...
Hinge Health reports record second quarter 2026 financial results; signs definitive agreement to acquire Cylinder Health
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the second quarter ended June 30, 2026 and provided a business update. “We delivered another stron...
Hinge Health announces publication of new study on adults using health platform
Hinge Health (HNGE) announced the publication of a new study that showed a significant reduction in the risk of falls and emergency room, ER, visits among adults aged 65+. The…
Study finds Hinge Health significantly lowers fall risk for adults aged 65+
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today the publication of a new study that showed a significant reduction in the risk of falls and emergency room (ER) visits a...
Hinge Health price target raised to $90 from $79 at Stifel
Stifel raised the firm’s price target on Hinge Health (HNGE) to $90 from $79 and keeps a Buy rating on the shares. The firm expects a modest Q2 beat and…
Hinge Health price target raised to $96 from $80 at Citizens
Citizens analyst Aaron Kimson raised the firm’s price target on Hinge Health (HNGE) to $96 from $80 and keeps an Outperform rating on the shares. The firm remains bullish on…
Hinge Health price target raised to $100 from $76 at Canaccord
Canaccord raised the firm’s price target on Hinge Health (HNGE) to $100 from $76 and keeps a Buy rating on the shares. The firm updated its model heading into the…
Hinge Health price target raised to $108 from $72 at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Hinge Health (HNGE) to $108 from $72 and keeps an Overweight rating on the shares. Q2 app downloads increased…
Hinge Health price target raised to $97 from $70 at Barclays
Barclays analyst Saket Kalia raised the firm’s price target on Hinge Health (HNGE) to $97 from $70 and keeps an Overweight rating on the shares. The firm adjusted targets in…